Ascendiant Capital Maintains Buy on GRI Bio, Raises Price Target to $36

Benzinga · 2d ago
Ascendiant Capital analyst Edward Woo maintains GRI Bio (NASDAQ:GRI) with a Buy and raises the price target from $35 to $36.